Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference

Published

WALTHAM, Mass., May 9, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of the Syndax management team will participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on Thursday, May 16, 2024, at 8:00 a.m. PT/ 11:00 a.m. ET.

A live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective menin inhibitor, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit. For more information, please visit www.syndax.com or follow the Company on X (formerly Twitter) and LinkedIn.

Syndax ContactSharon KlahreSyndax Pharmaceuticals, Inc.sklahre@syndax.comTel 781.684.9827

SNDX-G

 

Cision View original content:https://www.prnewswire.com/news-releases/syndax-announces-participation-at-the-bank-of-america-securities-2024-health-care-conference-302140895.html

SOURCE Syndax Pharmaceuticals, Inc.

In This Story

SNDX